Paclitaxel (Albumin-bound) Combined With Radiotherapy for the Treatment of Early Stage Nasopharyngeal Carcinoma

Nanjing University

Status and phase: Not yet enrolling; Phase 3

Conditions: Nasopharyngeal Carcinoma

Treatments: Drug: Albumin-Bound Paclitaxel

Study type: Interventional

Funder types: Other

Identifiers

NCT04766359

2020-236-02

Details and patient eligibility

About

This trial is a prospective, parallel controlled, randomized, open, multi-center phase III clinical trial. The trial will enroll 364 patients with nasopharyngeal carcinoma who are staged T1-2N0-1M0 (except T1N0M0) (UICC 8th edition) . This experiment was participated by multiple centers of Nanjing Gulou Hospital, Jiangsu Provincial People's Hospital, Jiangsu Cancer Hospital, Nanjing Military Region General Hospital, Jiangsu Provincial Hospital of Traditional Chinese Medicine, and Zhongda Hospital. Each center competes for admission of cases.

The subjects will be randomly assigned (using the random number table method according to the order of entry) to the experimental group to receive albumin-bound paclitaxel combined with IMRT concurrent radiotherapy, or the control group to receive cisplatin combined with IMRT concurrent radiotherapy.

Enrollment: 364 estimated patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Differentiated non-keratinizing carcinoma and undifferentiated non-keratinizing carcinoma confirmed by pathology;
• The staging is T1-2N0-1M0 (except T1N0M0) (UICC 8th edition);
• Initial treatment patients who have not received anti-tumor therapy;
• No history of other malignant tumors;
• Male or female, aged 18 to 70 years old;
• Liver and kidney function: total bilirubin ≤ upper limit of normal (ULN); AST and ALT ≤ 2.5 times ULN; alkaline phosphatase ≤ 5 times ULN; creatinine clearance ≥ 80 mL/min;
• Neutrophil count (ANC) ≥2×109/L, platelet count ≥100×109/L and hemoglobin ≥9 g/dL;
• No serious heart, lung, liver, kidney and other important organ dysfunction;
• Karnofsky score ≥70 points;
• Sign the informed consent form;
• Able to follow research protocols and follow-up procedures.

Exclusion criteria

• Anti-tumor treatment has been performed, including chemotherapy, radiotherapy, and surgery;
• Find distant metastases before treatment;
• Women who are pregnant or breastfeeding;
• Disagree to sign the informed consent form;
• Patients who cannot cooperate with regular follow-up due to psychological, social, family and geographic reasons;
• Simultaneously accept experimental treatment of other clinical research (in the treatment period of clinical research);
• Known to be allergic to possible chemotherapy drugs;
• Patients with other malignant tumors;
• Accompanied by severe uncontrollable infections or medical diseases, including autoimmune diseases;
• Major organ dysfunction, such as decompensated heart, lung, kidney, and liver failure, cannot tolerate radiotherapy and chemotherapy;
• Laboratory examination: total bilirubin>upper limit of normal (ULN); AST and/or ALT>1.5 times ULN and accompanied by alkaline phosphatase>2.5 times ULN;
• Any uncertain factors that affect patient safety or compliance.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

364 participants in 2 patient groups

Albumin-Bound paclitaxel combined with radiotherapy

Experimental group

Description:

Albumin paclitaxel (100mg/m2), D1 intravenous drip, start the first week of radiotherapy, use it continuously for 4-6 weeks. Radiotherapy: The total dose is 66-70Gy, divided into 33-35 times to complete.

Treatment:

Drug: Albumin-Bound Paclitaxel

Cisplatin combined with radiotherapy

Experimental group

Description:

Cisplatin (40mg/m2), D1 intravenous drip, start the first week of radiotherapy, use it continuously for 4-6 weeks. Radiotherapy: The total dose is 66-70Gy, divided into 33-35 times to complete.

Treatment:

Drug: Albumin-Bound Paclitaxel